App-Quantinova.ai

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥3 Lines of Therapy: A Real-World Evaluation in the United States

Allicia Girvan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dexamethasone

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Eva Telzerow - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display

Christi Ann Hayes - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Chepsy C Philip - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

Cytarabine liposomal

Discordance between Patient Goals and Treatment in Older AML Patients

Sara Marie Tinsley-Vance - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Mitchell S Cairo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Allopurinol

Financial Toxicity and Cost-Management Behaviors Among Patients with Myelodysplastic Syndromes

Kimberly Papay Rogers - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Thomas G. Knight - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Metformin Use and Incidence of Cancer: A Large Retrospective Cohort Study of U.S. Veterans

Maya Abdallah - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Metformin controlled release

Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis

John X Wei - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Demographic Disparities Related to Fertility Preservation Counseling in Patients Undergoing Bone Marrow Transplantation

Hayley Brianne Flanagan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The Launch of Two Sub-Studies of the Peak Registry, a Global, Longitudinal Study of Pyruvate Kinase Deficiency

Carl Lander - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

Association of Novel Urinary Protein Biomarkers with Persistent Albuminuria in Patients with Sickle Cell Disease

Laila Elsherif - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Interleukin

Uremic Metabolites Are Associated with Albuminuria and Estimated Glomerular Filtration Rate (eGFR) in Sickle Cell Disease

Laila Elsherif - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Clindamycin and Benzoyl Peroxide

Clinical and Epidemiological Features and Therapeutic Options of Avascular Necrosis in Sickle Cell Patients: A Cross-Sectional Study

Awni Alshurafa - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Hydroxyurea

Survey of Acceptance of Human Papillomavirus Vaccine Among Parents of Children Followed in Hematology/Oncology Clinic at a Single Institution in Louisiana

Lauren Raney - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Human papilloma virus vaccine

Rosai Dorfman's Disease with MAP2K1 Mutation Refractory to Chemotherapy with Complete Response to MEK Inhibitor Therapy: A Case Report

Gabriel Caixeta Vieira - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

Cyclophosphamide

A Bioinformatic Approach to the Clinical Evaluation of Linear Commitment Versus Cloud (Continuum of Low Primed UnDifferentiated) Models for Hematopoiesis Using Plinabulin Clinical Trial Data

Ramon W. Mohanlal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Cyclophosphamide

Profile of Perioperative Coagulation in Major Liver Resection for Cancer: A Prospective Observational Study

Patrick Van Dreden - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fibrinogen (IV)

Filters

41730 Abstracts